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Abstract  14 
Short chain fatty acids (SCFAs) have been recognized as mediators of immune responses, 15 
including pathways of cytokine production. In this study, we investigated the immune-16 
regulatory effects of SCFAs on human peripheral blood mononuclear cells (PBMCs) from 17 
buffy coat of healthy donors. PBMCs were exposed to varying concentrations of individual 18 
SCFAs or their mixtures, and, the production of interleukin (IL) IL-1β, IL-2, IL-6, IL-10, IL-19 
17 IL-21 IL-23 and transforming growth factor beta 1 (TGF-β1) were assessed. T cell 20 
differentiation after exposure to SCFAs was also examined. In comparison to LPS-stimulated 21 
cells (controls), SCFAs slightly decreased the production of TGF-β1 and significantly 22 
reduced IL-6 production (p < 0.05) and butyrate was more effective than acetate or 23 
propionate; non-stimulated cells did not respond to SCFAs. In addition, the viability of 24 
PBMCs was not significantly affected. SCFAs particularly butyrate caused the induction of 25 
CD4+CD25+ regulatory T cells (Treg) rather than Th17 cells. It is clear that. SCFAs may up-26 
regulate the production of anti-inflammatory cytokines in PBMCs resulting in the induction 27 
of CD4+CD25+ Treg cells.  28 
Key words: Short chain fatty acids, Human peripheral blood mononuclear cells, Cytokines, 29 
Immune modulation, T helper cells, Th17 and CD4+CD25+ Treg cells. 30 
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1. Introduction  32 
Short chain fatty acids (SCFAs) are a sub-group of fatty acids with 2 to 6 carbon atoms (C2 - 33 
C6 mono-carboxylic acids), formed principally from fermentation of prebiotics by anaerobic 34 
micro-organisms in the colon (Cummings & Macfarlane, 1991). SCFAs are predominant 35 
anions in human colon contents (Sellin, 1999). Relative proportions and amounts of SCFAs 36 
vary according to the type of fibre in the diet, type and population of microflora present in the 37 
colon and the gut transit time, absorption and utilization by colonic epithelium (Macfarlane & 38 
Macfarlane, 2003). Hence, the concentrations of SCFAs in the colon, portal blood and 39 
peripheral circulation are different. Total SCFAs in the colon has been estimated to range 40 
from 70 - 140 mM with concentration ratios of acetate, propionate and butyrate being, 10, 1.5 41 
and 2 mM, respectively (Bergman, 1990; Cummings, Pomare, Branch, Naylor, & 42 
Macfarlane, 1987; Sellin, 1999; Topping & Clifton, 2001). Whereas in the portal blood, 43 
concentrations are typically higher (0.375 mM) compared to that in peripheral circulation 44 
(0.079 mM) (Cummings et al., 1987). Likewise, Meijer, de Vos, and Priebe (2010) reported 45 
the total concentration of SCFAs in human peripheral blood to ranged from 0.050 – 0.1 mM 46 
and in portal blood, about 0.3 – 0.450 mM.  47 
SCFAs have been shown to have beneficial effect on human health; they are the favoured 48 
fuel of the colonic epithelium and are vital for intestinal and epithelial barrier functions 49 
(Adom & Nie, 2013; Scheppach, 1994). Lack of source of energy may lead to diminished 50 
integrity of epithelial function resulting in bowel disorders such as bowel inflammation 51 
(Harig, Soergel, Komorowski, & Wood, 1989; Wong & Jenkins, 2007). Furthermore, SCFAs 52 
stimulate colonic blood flow and enhance fluid and electrolytes uptake such as calcium 53 
absorption (Roy, Kien, Bouthillier, & Levy, 2006). Recent interest in SCFAs benefits have 54 
focused on their regulatory effects on immune responses by affecting the immune cells 55 
functions (Vinolo, Rodrigues, Nachbar, & Curi, 2011). SCFAs may ameliorate some 56 
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pathological conditions such as inflammatory bowel disease (IBD), possibly via their effect 57 
on immune responses (Tedelind, Westberg, Kjerrulf, & Vidal, 2007; Vernia et al., 1995; 58 
Vinolo et al., 2011). However, the mechanism of action is not clearly demonstrated but it has 59 
been reported that SCFAs may trigger cellular receptors such as G protein coupled receptors 60 
(GPCRs), (GPR41 and GPR43), of immune cells and subsequently initiate the immune 61 
response (Bindels, Dewulf, & Delzenne, 2013; Brown et al., 2003; Le Poul et al., 2003; 62 
Maslowski et al., 2009; Masui et al., 2013). Moreover, studies have suggested that butyrate 63 
and other SCFAs have inhibitory effects on the nuclear factor kappa B (NF-κB) signalling 64 
(Liu et al., 2012; Luhrs et al., 2001; Segain et al., 2000; Tedelind et al., 2007) and histone 65 
deacetylase (HDAC) (Aoyama, Kotani, & Usami, 2010; Waldecker, Kautenburger, 66 
Daumann, Busch, & Schrenk, 2008). SCFAs may regulate cytokine production (Cavaglieri et 67 
al., 2003; Masui et al., 2013; Yin, Laevsky, & Giardina, 2001), and, recently, butyrate and 68 
propionate have been noted to promote peripheral regulatory T cell (Treg)differentiation 69 
which might contribute to immune homeostasis (Arpaia et al., 2013).  70 
PBMCs compose mainly of lymphocytes, macrophages and monocytes. The lymphocyte 71 
population in healthy human adults consists of approximately 60% T cells (CD4+ and CD8+) 72 
and 35% B cells, natural killer cells (NK), macrophage and monocytes (Minoprio, 2000; 73 
Plebanski, 2002). PBMCs have been widely used in immunological and pharmaceutical 74 
studies probably due to their properties, which relate to sophisticated immune cells. The cells 75 
are co-cultured with different types of immune suppressant or stimulant drugs to study and 76 
determine their efficiencies using different parameters of immune responses such as the 77 
release of immune mediators (cytokines) (Ramachandran et al., 2012). T lymphocytes can be 78 
functionally distinguished into cytotoxic (Tc) and helper (Th) cells. Human naive CD4+ T 79 
helper cells can be divided into different functional subsets Th1, Th2, Th17, and Treg cells 80 
according to surface phenotype and cytokine secretion (Luckheeram, Zhou, Verma, & Xia, 81 
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2012). Th1 cells express T-box transcription factor (Tbet-2) and release IL2, TNFα and IFNγ 82 
cytokines and act against intracellular pathogens. Th2 express GATA3, produce anti-83 
inflammatory cytokines such as IL-1 receptor antagonist (IL-1ra), IL-4, IL-5, IL-6, IL-10 and 84 
IL-13, and stimulate humoral immune responses against extracellular pathogens. Th17 cells 85 
express the up-regulation of transcription factors, such as RORγt and STAT-3, release pro-86 
inflammatory cytokines IL-17 and play a role in organ-specific autoimmune diseases 87 
(Thomas Korn, Oukka, Kuchroo, & Bettelli, 2007). Treg cells express FoxP3 and produce IL-88 
10 and TGF-β cytokines, promote tolerance to self and non-pathogenic antigens, suppress 89 
amplitude immune and inflammatory responses, drive and modulate immune responses, and 90 
abrogate autoimmune diseases (Wan & Flavell, 2009).  91 
Mature CD4+ Th cells are also involved in autoimmunity, during T cell receptor (TCR) 92 
activation in a particular cytokine milieu, naive CD4 T cells may differentiate into one of 93 
several lineages of Th cells, including Th1, Th2, Th17, and induce Treg cells (iTreg) as 94 
defined by their pattern of cytokine production and function. Imbalance of either pattern of 95 
Th1 or Th2 cells may cause autoimmune disease e.g. a dysregulation of T helper cell 96 
phenotype in favour of Th1 appears to underlie Crohn’s disease, a form of IBD (Dionne, 97 
Ruemmele, & Seidman, 2004). Along with Th1 and Th2 cells, (FoxP3) Treg and Th17 cells 98 
have been recognized as significant players in immune balance (Brand, 2009). The effect of 99 
SCFAs on Treg cells may subsequently regulate the induction of Th1, Th2 and Th17 and 100 
maintaining the immune homeostasis, thus SCFAs may be valuable to maintain the immune 101 
homeostasis and prevent of chronic inflammation (Bailon et al., 2010; Vinolo et al., 2011).  102 
SCFAs particularly butyrate have been known to modulate immune responses (Cox et al., 103 
2009; Vinolo et al., 2011). However, little is known about the effects of SCFAs on human 104 
PBMCs. Herein we evaluated the regulatory effects of SCFAs in PBMCs and the induction of 105 
Treg and/or Th17 cells. The regulatory effect of SCFAs in the production of pro- and anti-106 
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inflammatory cytokines with PBMCs in the presence or absence of LPS stimulation was also 107 
examined. 108 
2. Material and methods  109 
2.1. Chemicals and reagent  110 
Biological grade acetate, propionate, butyrate, purified LPS from Escherichia coli O111:B4 111 
and growth medium Roswell Park Memorial Institute medium (RPMI-1640) were purchased 112 
from Sigma (Sigma-Aldrich, Sydney, Australia). Ficoll-Paque™ Plus was from GE 113 
Healthcare (GE Healthcare, Bio-Sciences, Uppsala, Sweden). Antibiotic-Antimycotic 114 
solution and Fetal bovine serum (FBS) were acquired from Gibco Life Technologies 115 
(Gibco®Life Technologies, Mulgrave, Australia). Phosphate-Buffered Saline (1X) pH 7.4, 116 
(PBS) was from Invitrogen (Invitrogen Pty Ltd., Mount Waverly, Victoria, Australia),The 117 
Buffy coat was provided by the Australian Red Cross Blood Services, Melbourne, Australia, 118 
Other reagents and chemicals were of biotechnological and molecular-biology grade from 119 
Sigma-Aldrich unless otherwise stated.  120 
2.2. Isolation of human PBMCs from buffy coat using Ficoll gradient 121 
In order to meet the requirements of the National Health and Medical Research Council 122 
“National Statement on Ethical Conduct in Human Research” (National Health and Medical 123 
Research Council, 2007), the Human research ethics of the proposed project was accepted 124 
and approved by the Chair of the Faculty of Health, Engineering, and Science, Victoria 125 
University Human Research Ethics Committee. A contract agreement was also conducted 126 
with Australian Red Cross Blood Services Melbourne Australia, in order to the supply of 127 
buffy coat. 128 
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PBMCs were isolated from human buffy coat by Ficoll-Paque gradient according to the 129 
method described by (Donkor et al., 2012) with minor modifications. Briefly, individual 130 
buffy coat (60 mL) was diluted with an equal volume of phosphate buffer saline (PBS) and 131 
layered on Ficoll-Paque Plus (GE Healthcare, Bio-Sciences, Uppsala, Sweden). Cells at the 132 
interphase were collected following centrifugation (680 g, 25 min, 18°C) (Sorvall® RT7 133 
centrifuge; DuPont, Newtown, CT, USA). Separated layers PBMC were washed twice in cold 134 
PBS, and following centrifugation (680 g, 10 min, 18°C). To lyse any remaining red blood 135 
cells, the pellet was resuspended in 5 mL red blood cell lysing buffer; Ammonium-Chloride-136 
Potassium (ACK) (Gibco® ACK  Life Technologies) and incubated for 8 min at room 137 
temperature. The volume was then adjusted to 35 mL using sterile PBS then centrifuged 138 
(680 g, 10 min, 18°C). Following two subsequent washes, the cell pellet was resuspended in 139 
RPMI1640 medium supplemented with 10% FBS and 1% of Antibiotic-Antimycotic solution 140 
for co-culture and stimulation. 141 
2.3. Co-culture and stimulation of PBMCs by SCFAs 142 
Human PBMCs were seeded in flat bottom 6-well tissue culture plates (Corning, Sigma) at 143 
final concentration 1 × 106 cells/mL RPMI1640 medium per well, either in RPMI1640 144 
medium alone or with LPS (controls), medium with LPS and acetate, propionate, butyrate or 145 
mixed SCFAs. The concentrations of SCFAs were 1, 1.5, 2 mM similar to physiological 146 
concentration found in the colon and peripheral circulation (portal vein) (Cummings et al., 147 
1987; Topping & Clifton, 2001), similar concentrations were also used in previous studies 148 
(Liu et al., 2012; Nancey et al., 2002; Weber & Kerr, 2006). LPS (5 μg/mL) was used for 149 
cells stimulation (Chen, Bruns, Donnelly, & Wunderink, 2010; Jansky, Reymanova, & 150 
Kopecky, 2003). The plates were incubated at 37°C in a 5% CO2 incubator for 48 hours.  151 
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To investigate the responses of PBMCs to the stimuli (LPS and/or SCFAs), the cells were 152 
stimulated with 5µg/mL LPS alone (Chen et al., 2010), with SCFAs only or a combination of 153 
LPS and SCFAs for 48 h. PBMCs were also stimulated  with LPS for 24 hour then SCFAs 154 
were added and cells further incubated for another 24 hours. 155 
2.4. PBMCs viability assay  156 
PBMCs viability in presence of LPS and/or SCFAs were assessed using MTS (3-(4,5-157 
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2- (4-sulfophenyl)-2H-tetrazolium, inner 158 
salt) assay (CellTiter 96® AQueous One Solution Cell Proliferation Assay, Promega, USA) 159 
according to manufacture instruction. Briefly, cells were seeded in 96-well plates (Corning, 160 
Sigma) at concentration 1 × 103 cells per 100 µL of growth media with or without various 161 
stimuli (as above), and then incubated for 48 h at 37°C in a 5% CO2 incubator. The viability 162 
was detected by adding 20 µL of MTS solution, followed by 4 h of incubation then 163 
absorbance was read at 490 nm using iMark Microplate Absorbance Reader (BIO-RAD, 164 
Australia). After subtracting of the background reading, cell viability was calculated as:  165 
% viable cell = (Optical density (OD) of SCFAs treated sample / OD of control sample) x 166 
100. 167 
2.5. ELISA analysis of cytokines  168 
Supernatants from stimulated and non-stimulated PBMCs cultures were collected and 169 
analysed for cytokines concentrations using BD OptEIA ELISA kits (BD Bioscience, San 170 
Diego, CA), including IL-1β, IL-2, IL-6, IL-10, IL-17, IL-21 TGF-β1 and IL-23. The 171 
detection procedures were performed in accordance with the manufacturer’s instructions. 172 
Cytokines were measured at 24 and 48 hours of stimulation. Data are expressed as the mean 173 
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cytokine response minus background (pg/ml) of each treatment from triplicate wells, plus or 174 
minus the standard error of the mean.  175 
2.6. Measurement of nitric oxide production 176 
Nitric oxide (NO) production from stimulated PBMCs and non-stimulated PBMCs was 177 
measured spectrophotometrically using Griess Reaction Assay (Promiga, Auburn, Australia) 178 
according to the manufacture’s instruction. Briefly, after co-culture and stimulation of 179 
PBMCs (as above), 50 µL aliquots of supernatant were incubated with 100 µL Griess reagent 180 
(50 µL of 1% sulfanilamide in 0.1 M HCl and 50 µL of 0.1% N-1-napthylethylenediamine 181 
dihydrochloride) for 10 min at room temperature. Absorbance was read at 550 nm using 182 
iMark Microplate Absorbance Reader (BIO-RAD, Australia) and results were calculated 183 
based on a NaNO2 standard curve. 184 
2.7. Flow Cytometry Analysis of Th17 and Treg cells  185 
Activated PBMCs were collected and analysed for induction of Treg/Th17 cells. Briefly, 1 186 
mL suspension PBMCs culture was collected and centrifuged at 500g for 10 min, cell pellet 187 
was washed twice using fluorescence activated cell sorting  (FACS) buffer (PBS + 2% FBS) 188 
and the suspension was centrifuged again at 500g for 10 min. PBMCs were re-suspended at 1 189 
× 106 cells/ml in FACS buffer and surface marker staining was performed using fluorescein 190 
isothiocynate (FITC)-labelled anti-human CD4, allophycocyanin labelled anti-human 191 
CD25/CD3 (Becton-Dickinson), peridinin chlorophyll protein (PerCP)-labelled anti-human 192 
CD3 (Biolegend, San Diego, CA, USA) and PerCP cyanine (Cy)5.5-labelled anti-human 193 
CCR6 (CD196). Intracellular staining was performed using phycoerythrin (PE)-labelled anti-194 
human FoxP3/RORγt (BD Pharmingen and R&D Systems, Minneapolis, MN, USA, 195 
respectively), according to the manufacturer’s instructions. Samples were read using a BD 196 
FACSCalibur and data was acquired using CellQuest program (Becton Dickinson 197 
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Biosciences). Analysis was performed using Gatelogic version 3.07 software (Inivai, 198 
Victoria, Australia). Absolute numbers of Treg and Th17 cells were calculated as a 199 
percentage of the total lymphocyte number (Donkor et al., 2012). 200 
2.8. Statistical analysis 201 
The results obtained were analysed as a split plot in time design with three main factors: 202 
SCFAs (Three fatty acids) and their doses (3 dose levels) as the main plot and time (two time 203 
frame 24 and 48) LPS was used as stimulant. The statistical evaluations of the data were 204 
performed using the general linear model (GLM) (SAS/STAT., 1996). Significant differences 205 
between treatments were tested by analysis of variance (ANOVA) followed by a comparison 206 
between treatments performed by Fisher’s least significant difference (LSD) between each 207 
sample with a level of significance of (p < 0.05). Data are expressed as mean and standard 208 
deviation of triplicate measures determined in 5 independent experiments. 209 
3. Results 210 
3.1. PBMCs viability, proliferation and NO production 211 
The MTS assay of PBMC viability and proliferation with or without different stimuli is 212 
shown in Figure 1. Proliferation of PBMC were potentiated in the presence of LPS in all 213 
samples compared with non LPS-stimulated PBMCs. Relatively similar effects resulted in the 214 
presence of each SCFA with maximum proliferation observed in the presence of butyrate 215 
followed by mixed SCFAs over 48 h.Similar LPS effect on PBMCs proliferation was 216 
reported (Jansky et al., 2003), and SCFAs did not induce cell apoptosis at used concentration.  217 
Production of NO was enhanced in the presence of LPS, whereas the addition of SCFAs 218 
induced remarkable reduction (p < 0.05) of NO (Fig. 2). After 48 h of incubation, NO was 219 
reduced by 38.3% in the presence of butyrate and 29.9% in acetate and propionate compared 220 
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with LPS-stimulated cells, However the inhibition of NO in the SCFA mixture was similar to 221 
that of butyrate.  222 
3.2. Production of cytokines 223 
Figure 3 (A-H) show cytokines (IL-β1, IL-2, IL-6, IL-17, IL-21 IL-23 and TGF-β1) produced 224 
by PBMCs in the presence of LPS compared with non-stimulated PBMCs, the combination 225 
of LPS and SCFAs or SCFAs only. Results show significant (p < 0.05) decrease in IL-β1, IL-226 
2, IL-6, IL-17 and IL-21, with a slight reduction of IL-23 and TGF-β1 in the presence of 227 
SCFAs, compared to cells stimulated with LPS only. However, IL-10 secretion was not 228 
affected by LPS  compared to non LPS-stimulated cells but it was increased in the presence 229 
of SCFAs particularly in butyrate (Säemann et al., 2000). We have also noted similar results  230 
when PBMCs stimulated with LPS for 24 h followed by addition of SCFAs and incubated for 231 
another 24 hours (Table 1). 232 
3.3. CD4+ CD25; Th17 and Treg populations  233 
Flow cytometric analysis of LPS and SCFAs stimulated PBMCs showed increased CD4+ 234 
CD25+ Treg and Th17 cells compared to unstimulated cells (Fig. 4). LPS aloneincreased the 235 
Th17 cell population compared to Treg cells after 48 h of incubation. In the presence of 236 
SCFAs particularly butyrate, the relative proportion of Th17 and Treg showed slight increase 237 
of Treg cells compared to Th17 (Fig. 4). The addition of SCFAs along with LPS at 0 time or 238 
after the pre-stimulated PBMCs with LPS, showed comparatively similar up-regulation of 239 
Treg cells after 24 h compared to unstimulated cells (control). Butyrate was more effective in 240 
induction of Treg cells than acetate or propionate. The addition of mixed SCFAs did not 241 
induce augmentation of the effects as compared with each SCFA. However, their effects 242 
were concentration-dependent; 2 mM of SCFAs was more effective in up-regulation of Treg 243 
than 1 and 1.5 mM, (Fig. 4).  244 
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4. Discussion 245 
Despite most of intestinal SCFAs being used by intestinal epithelium cells, a considerable 246 
amount of acetate, propionate, and butyrate are absorbed into the blood and exert their effects 247 
at peripheral tissue level beyond the digestive system through regulation of immune 248 
responses (Matsumoto et al., 2006). Consequently, we assumed that SCFAs might have 249 
regulatory effects on peripheral PBMCs. Therefore, in the current study, we used in vitro 250 
LPS-stimulated PBMCs of healthy donor to compare the anti-inflammatory effect of acetate, 251 
propionate, and butyrate and regulation of Th17 and Treg balance. It was found that SCFAs 252 
reduced the production of pro-inflammatory factors including IL-1β, IL-6, IL-17 and NO 253 
whereas they enhanced the production of anti-inflammatory mediators such as IL-10, and IL-254 
2. Furthermore, SCFAs affected gene expression of T helper cells possibly through their 255 
effect on immune mediators and growth factors such as IL-6 and TGF-β1, which might have 256 
led to the up-regulation of Treg cells. Interestingly, SCFAs exhibit these effects mainly in 257 
LPS-stimulated PBMCs whereas non LPS-stimulated cells were not affected by SCFAs. 258 
4.1. Effect of SCFAs on cells viability  259 
To determine whether SCFAs exert their effects through stimulation of PBMCs but not via 260 
induce cellular death, MTS assay was conducted after co-culturing of PBMCs with LPS and 261 
SCFAs (Fig. 1). Cell growth was slightly potentiated in the presence of LPS and SCFAs 262 
particularly butyrate or mixed SCFAs, indicating that viability of cells was not affected by 263 
experimental conditions. Furthermore, slight proliferation of PBMCs following LPS exposure 264 
in all samples indicated that the proliferation was mainly due to stimulation effect of LPS and 265 
that the SCFAs only promoted the LPS activated cell proliferation. The induction of cell 266 
proliferation indicate that LPS was able to trigger cell response and initiate the immune 267 
activity in PBMCs, involving B lymphocytes, T lymphocytes, dendritic cells, natural killer 268 
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cells, monocytes, and macrophages. This was expected as LPS is known to induce a 269 
macrophage-dependent immune response through activation of NF-κB transcription factor, 270 
subsequently enhancing proliferation and release of immune factors from PBMCs (Martich, 271 
Boujoukos, & Suffredini, 1993; Sharif, Bolshakov, Raines, Newham, & Perkins, 2007). In 272 
our study, acetate, propionate and butyrate did not cause apoptosis in PBMCs but promoted 273 
the proliferation of LPS-stimulated PBMCs. Different effects of SCFAs on proliferation of 274 
PBMCs and other similar cells have been highlighted (Meijer et al., 2010). A study on the 275 
effect of SCFAs in mouse macrophage cell line RAW264.7 reported that viability of cells 276 
was not affected when incubated with 0 - 1.2 mM SCFAs (Liu et al., 2012). Similarly, an 277 
earlier study demonstrated that unstimulated PBMCs were not affected by SCFAs at a 278 
physiological level (Cox et al., 2009). On the other hand some studies showed that butyrate 279 
caused apoptosis in antigen stimulated T cells and macrophages (Bailon et al., 2010; Kurita-280 
Ochiai, Fukushima, & Ochiai, 1999). For example, 2 mM of butyric acid induced inhibition 281 
of proliferation after concanavalin-A stimulated porcine PBMCs (Weber & Kerr, 2006). 282 
Another study revealed that lymphocytes proliferation was inhibited due to 1.5 mM of 283 
butyrate but not acetate or propionate at the same concentration (Cavaglieri et al., 2003). 284 
These different effects of SCFAs might be due to the using of different concentrations, 285 
sources of PBMCs and method of stimulation (Meijer et al., 2010).   286 
4.2. Effect of SCFAs on cytokine release  287 
Lymphocytes besides inflammatory cells are involved in immune and inflammatory 288 
responses. They interact with each other via release of cytokines and expression of cytokine 289 
receptors in response to stimuli (Gruys, Toussaint, Niewold, & Koopmans, 2005). Cytokines 290 
can act as positive or negative regulators of immune responses and maintain lymphocyte 291 
balance. Nevertheless, the activity of cytokines are dependent upon each other along with 292 
environmental signals and receptor expression on effector cell surfaces (Scheller, Chalaris, 293 
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Schmidt-Arras, & Rose-John, 2011). Factors affecting cytokine network may subsequently 294 
influence the inflammatory or immune response. Among these factors, SCFAs which have 295 
been recognized as regulators of immune response through different mechanisms, such as 296 
directly affecting the immune cells by binding to specific receptors GPCR (Le Poul, et al., 297 
2003), inhibition of HDAC (Davie, 2003), suppression of activation of the transcription 298 
factor NF-κB (Segain et al., 2000) and revelling different anti-inflammatory activities via 299 
regulation of cytokines secretion by immune cells (Cox et al., 2009; Saulnier, Spinler, 300 
Gibson, & Versalovic, 2009). 301 
The current study highlights the effect of SCFAs on secretion of cytokines that are involved 302 
in T cell differentiation into either Th17 or Treg cells besides the main cytokines that are 303 
released by Th17 and Treg. Stimulation of PBMCs with LPS alone lead to an increased 304 
production of IL-6 and TGF-β as LPS is a known stimulant to induce the secretion of pro-305 
inflammatory cytokines (Jansky et al., 2003; Martich et al., 1993; Sharif et al., 2007). The 306 
combination of LPS and SCFAs particularly butyrate decreased IL-6 and marginally reduced 307 
TGF-β1. These effects were similar for either SCFAs added to 24 h pre-stimulated PBMCs or 308 
at 0 time of stimulation (Table 1 and Fig. 3). The reduction of IL-6 and slightly reduced TGF-309 
β1concentration in the pre-stimulated PBMCs was probably due to the neutralizing and 310 
inhibiting effects of SCFAs on pro-inflammatory condition in stimulated PBMCs. This might 311 
have mediated the secretion of anti-inflammatory cytokines that likely act as immune 312 
regulator of pro-inflammatory cytokines (Dinarello, 1997; Opal & DePalo, 2000; Sultani, 313 
Stringer, Bowen, & Gibson, 2012). The effect of SCFAs on immune cells depends on the 314 
activation status and differentiation stages of effector cells (Cox et al., 2009). Furthermore, 315 
incubation of PBMCs in the presence of SCFAs without LPS did not induce changes in the 316 
release of tested cytokines an indication that the physiological concentrations of SCFAs had 317 
no obvious effects under our study conditions unless the cells were primed with LPS. 318 
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TGF-β1 has verity of functions, the exposure of PBMCs to TGF-β1 can generate a variety of 319 
cellular processes including inhibition of proliferation, differentiation, migration and 320 
apoptosis (Sanchez-Capelo, 2005). TGF-β1 regulates many other growth factors and plays a 321 
role in naive cell differentiation based on its concentration and other cytokine environment. 322 
TGF-β1 in the presence of IL- 6 , IL-1β,  IL-21 or IL-23  drive cell differentiation to Th17 323 
cells, subsequently releasing more pro-inflammatory factors (Yoshimura, Suzuki, Sakaguchi, 324 
Hanada, & Yasukawa, 2012; Liang Zhou, Chong, & Littman, 2009; Liang Zhou et al., 2007). 325 
Little is known about effects of SCFAs on release of TGF-β1 in human PBMCs, in our study 326 
important pleiotropic cytokine, TGF-β1 was increased significantly in the presence of LPS 327 
but only slight decrease with SCFAs. Increase in the concentration of IL-6 along with TGF-328 
β1 could trigger differentiation of CD4+ to Th17 cells. The induction of Th17 cells could be 329 
related to the down-regulation of IL-6 but not TGF-β1 since the level of TGF-β1 was not 330 
significantly affected by SCFAs. Consistent with our study SCFAs have been reported to 331 
supress pro-inflammatory mediators such as TNF-α, IL-6 and enhance the release of anti-332 
inflammatory cytokine IL-10 (Meijer et al., 2010; Park, Lee, Lee, Kim, & Kim, 2007). 333 
Pleiotropic cytokines TGF-β1 plays important role in regulation of immune response by 334 
acting with other cytokines such as IL-2 and IL-10 to promote expression and activation of 335 
Treg cells, and released more IL-2 and IL-10, consequently up-regulating anti-inflammatory 336 
condition and ameliorates inflammation (Taylor, Verhagen, Blaser, Akdis, & Akdis, 2006).  337 
4.3. Differentiation of CD4+ cells 338 
Based on the cytokine milieu, activated naïve T helper cells may be differentiated into Th1, 339 
Th2, Th17 or Treg phenotypes with different effector roles and cytokine profiles (Broere, 340 
Apasov, Sitkovsky, & van Eden, 2011). IL-12 milieu skews CD4+ T helper cells to Th1, IL-4 341 
skews CD4+ T helper cells to Th2, TGF-β1 skews CD4+ T helper cells to Treg and IL-6 with 342 
TGF-β skews CD4+ T helper cells to Th17 (Afzali, Lombardi, Lechler, & Lord, 2007; 343 
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Kimura & Kishimoto, 2010; Ramgolam, Sha, Jin, Zhang, & Markovic-Plese, 2009). 344 
Furthermore other cytokines also play a role in cell differentiation and activation such as IL-2 345 
which act with TGF-β1 to drive CD4+ T cells to Treg cells (Campbell & Koch, 2011; Zheng, 346 
2013; Ziegler & Buckner, 2009) and TGF-β with IL-1β, IL-21, and IL-23 are implicated in 347 
promoting human Th17 differentiation (T. Korn, Bettelli, Oukka, & Kuchroo, 2009; 348 
Ramgolam et al., 2009; Yang et al., 2008; Zheng, 2013; Ziegler & Buckner, 2009). In our 349 
study the, down regulation of Th17 cells may due to decline of IL-21 and IL-23 rather than 350 
reduction of TGF-β which was relatively stable in our study condition (Fig. 3).  351 
Treg cells and Th17 cells are two subtypes of CD4+ cells. They play opposing roles in 352 
autoimmune inflammatory diseases and immune tolerance, although they share a common 353 
differentiation pathway. Imbalance of Treg and Th17 has been established in several 354 
autoimmune diseases (Ji et al., 2012). Recent studies in human and mouse CD4+ T cells show 355 
dichotomy in the generation and differentiation of Treg cells and Th17 cells (Kimura & 356 
Kishimoto, 2010; Zhu, Yamane, & Paul, 2010). The TGF-β1 signalling is described as the 357 
co-expression of Foxp3 and RORγ-t (L. Zhou et al., 2008). This signalling depends on other 358 
immune factors. For example, TGF-β1 alone enhances Foxp3 expression and inhibits RORγ-t 359 
activity, whereas combination of TGF-β1 with either IL-1β and IL-23 or IL-21 and IL-6 360 
drives human Th17 differentiation (de Jong, Suddason, & Lord, 2010). This  indicates the 361 
inner correlation between Th17 and Treg cells through the cytokine milieu (Ji et al., 2012).  362 
SCFAs are supposed to have a regulatory influence on inflammatory disorder and ameliorate 363 
inflammation in some intestinal inflammatory disorders (Cox et al., 2009). This might be 364 
mediated through modulation of cytokine milieu in the medium and expression of Treg and 365 
Th17. Our finding exhibited that Foxp3 and RORγ-t expression in T lymphocytes subset 366 
population resulted after incubation of LPS stimulated PBMCs with different SCFAs. The 367 
stimulation of PBMCs with LPS elicited Th17 promoting cytokines mainly TGF-β1 and IL-6 368 
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leading to increased frequency of Th17 and the subsequent release of IL-17 and IL-21. 369 
However in the presence of SCFAs, Th17 cell differentiation was likely supressed and 370 
favoured cytokine environment for FoxP3 regulatory cell induction leading to enhanced 371 
FoxP3 expression. Butyrate was more effective in this regard than acetate and propionate. 372 
These findings are consistent with studies suggesting that butyrate showed strong anti-373 
inflammatory properties (Cavaglieri et al., 2003; Liu et al., 2012; Meijer et al., 2010; 374 
Tedelind et al., 2007) Furthermore, Arpaia et al. (2013) and  Furusawa et al. (2013) reported 375 
that butyrate promotes the regulation of intestinal Treg generation. However, the effect of 376 
SCFAs on T cell phenotypes need more studies. 377 
5. Conclusion 378 
SCFAs may have in vitro anti-inflammatory and immune regulatory effects through induction 379 
of Treg cells and production of anti-inflammatory cytokines. Butyrate showed more 380 
regulatory effect than propionate and acetate respectively. Our finding indicates that, SCFAs 381 
may have regulatory properties on inflammatory processes via the balance of Th17/Treg cells 382 
and pro and anti-inflammatory cytokines. 383 
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List of figures: 612 
Fig. 1. 613 
MTS assay examining the effects of SCFAs on the viability and proliferation of PBMCs. 614 
Cells were sub-cultured in 96 well plates at initial density of 103 cells per 100 μL with or 615 
without SCFAs and/or LPS and incubated for 48 h. PBMCs in growth media was set as 616 
control. Cells viability (%) = (OD of SCFAs treated sample / OD of control sample) ×100. 617 
Ace = acetate, Pro = propionate, But = Butyrate, PBMCs = Peripheral blood monocular cells. 618 
Results are expressed as mean of five independent experiments with error bars showing the 619 
standard deviation, (p < 0.05).  620 
 621 
Fig. 2.  622 
Nitric oxide (NO) concentration (µM) in supernatants of stimulated PBMCs (1× 106 cells/ 623 
mL) cultures. PBMCs were sub-cultured for 48 h either in the presence of LPS (5 μg/mL), 624 
LPS with each SCFA (acteate, propionate or butyrate) or LPS with the mixed SCFAs. RPMI 625 
media only was used as a control. Supernatants were collected after 24 h and 48 h and the 626 
level of NO was determined by the Griess reaction. NO levels were significantly different (p 627 
< 0.05) from the control values (bars with different letter). NO = Nitric oxide; LPS = 628 
Lipopolysaccharide; Ace = acetate; Pro = propionate; But = butyrate; SCFAs = short chain 629 
fatty acids. Data represent the mean of five independent experiments with error bars showing 630 
the standard deviation. 631 
 632 
Fig. 3. 633 
Cytokine concentrations of IL-1β (A), IL-2 (B), IL-6 (C), IL-10 (D), IL-17 (E), TGF-β1 (F),  634 
IL-21 (G) and IL-23 (H) in supernatant after PBMCs (1 × 106 cells/mL) were sub-cultured 635 
with either acetate, propionate, butyrate or mixed SCFAs for 24 h and 5 μg/mL. LPS was 636 
added to each well and incubated for a further 24 h or 48 h. PBMCs with LPS only was set as 637 
control. Data represent the mean of five independent experiments with error bars showing the 638 
standard deviation, (bars with different letter are significantly different (p < 0.05)). SCFAs = 639 
short chain fatty acids; IL = interleukin; TGF = transforming growth factor; Ctrl = control, 640 
LPS = Lipopolysaccharide, Ace = acetate, Pro = propionate, But = butyrate, Mix = Mixed 641 
SCFAs. 642 
 643 
Fig. 4.  644 
Expression of activation marker CD25 on T lymphocytes, plots were gated on CD3 (A), 645 
percentage of induced CD25+ forkhead box protein 3 (FoxP3+) (B), and induction of ROR-γt 646 
expressing T helper type 17 (Th17) (C) by PBMCs in response to LPS and/or SCFAs.  647 
 648 
  649 
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Table 1  650 
Cytokine levels (pg/mL) produced by PBMCs co-cultured with LPS only for 24 h then SCFAs were added and the cells were incubated for 651 
another 24 h.   652 
Cytokines T(h) Ctrl LPS Ace Pro But Mix 
IL-β1  24 55.04 ±6.3 1587.1 ±203.8 1571.7 ±130.2 1275.2 ±51.2 1601.1± 105.4 1620.1 ±33.0 48 53.13 ±5.8 1828.2 ±166.4 1031.7 ±35.5 1121.2 ±48.4 992.5 ±166.3 1086.3 ±143.0 
        
IL-2 24 17.33 ±0.5 285.13 ±5.1 291.32 ±12.2 287.23 ±8.5 290.1 ±41.7 289.21 ±6.1 48 15.46 ±1.3 346.21 ±21.1 225 ±31.5 234 ±19.8 201.3 ±32.2 222 ±7.6 
        
IL-6 24 59.36 ±3.3 1082.07 ±20.6 1001.21 ±25.7 1013 ±5.1 1014.12 ±83.3 997.39 ±64.6 48 71.41 ±5.2 1097.13 ±11.9 831.3 ±32.4 942 ±25.1 612 ±32.9 741 ±46.2 
        
IL-10 24 71.12 ±4.2 76.18 ±3.6 78.3 ±13.3 88.1 ±1.2 87.23 ±4.8 76.91 ±3.5 48 77.34 ±3.2 74.75 ±2.8 181.2 ±6.4 173.15 ±8.1 26 ±12 263 ±20.8 
        
IL-17 24 74.13 ±5.3 403.17 ±34.1 423.1 ±8.7 411.1 ±21.1 435.2 ±23.0 429.19 ±46.4 48 78.41 ±1.9 432 ±14.1 107.4 ±2.8 172 ±5.3 121 ±10.5 133 ±16.8 
        
IL-21 24 231.12 ±14.4 371.41 ±6.9 372.42 ±95.9 358 ±18.5 364.3 ±28.0 361.1 ±17.1 48 236.71 ±12 391.35 ±19.9 62.21 ±3.3 117.7 ±5.9 61.5 ±9.4 75.13 ±4.0 
        
IL-23 24 81.28 ±3.8 1271 ±89.8 1237 ±175.1 1211.5 ±81.1 1301 ±178.4 1291 ±38.3 48 86.30 ±3.2 1295 ±116.0 920 ±34.1 989 ±32.1 931.2 ±11.7 1011 ±26.8 
        
TGF-β1 24 161.1 ±9.1 1751 ±127.5 1723 ±108.2 1715 ±81.1 1695.4 ±17.7 1699 ±116.5 48 156.3±4.1 1950±38.4 1710±46.1 1608±135.6 1651±31.5 1558±174.0 
IL = interleukin; TGF-β1 = transforming growth factor beta 1; Ctrl = control (PBMCs without stimulation), LPS = Lipopolysaccharide, Ace = 653 
acetate, Pro = propionate, But = butyrate, Mix = Mixed SCFAs.  654 
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Fig. 2. 658 
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Fig. 3. 660 
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 Fig. 4. 
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